Aliases & Classifications for Thyroid Cancer

MalaCards integrated aliases for Thyroid Cancer:

Name: Thyroid Cancer 12 76 37 29 29 55 43 15
Thyroid Carcinoma 12 29 55 15 73
Neoplasm of the Thyroid Gland 29 6
Thyroid Neoplasm 12 73
Malignant Neoplasm of Thyroid Gland 12
Malignant Tumour of Thyroid Gland 12
Head and Neck Cancer, Thyroid 12
Malignant Neoplasm of Thyroid 73
Neoplasm of Thyroid Gland 12
Thyroid Gland Neoplasm 12
Thyroid Neoplasms 44

Classifications:



External Ids:

Disease Ontology 12 DOID:1781 DOID:3963
ICD10 33 C73
ICD9CM 35 193
MeSH 44 D013964
KEGG 37 H00032

Summaries for Thyroid Cancer

MedlinePlus : 43 Your thyroid is a butterfly-shaped gland in your neck, just above your collarbone. It makes hormones that help the body work normally. There are several types of cancer of the thyroid gland. You are at greater risk if you Are between ages 25 and 65 Are a woman Are Asian Have a family member who has had thyroid disease Have had radiation treatments to your head or neck You should see a doctor if you have a lump or swelling in your neck. Doctors use a physical exam, thyroid tests, other blood and imaging tests, and a biopsy to diagnose thyroid cancer. Treatment depends on the type of cancer you have and how far the cancer has spread. Many patients receive a combination of treatments. They may include surgery, radioactive iodine, hormone treatment, radiation therapy, chemotherapy, or targeted therapy. Targeted therapy uses substances that attack cancer cells without harming normal cells. NIH: National Cancer Institute

MalaCards based summary : Thyroid Cancer, also known as thyroid carcinoma, is related to thyroid cancer, nonmedullary, 2 and thyroid carcinoma, familial medullary, and has symptoms including coughing, snoring and tinnitus. An important gene associated with Thyroid Cancer is BRAF (B-Raf Proto-Oncogene, Serine/Threonine Kinase), and among its related pathways/superpathways are Thyroid cancer and Transcriptional misregulation in cancer. The drugs Cometriq and Lenvima have been mentioned in the context of this disorder. Affiliated tissues include the thryoid gl, thyroid and lymph node.

Disease Ontology : 12 An endocrine gland cancer located in the thryoid gland located in the neck below the thyroid cartilage.

Wikipedia : 76 Thyroid cancer is cancer that develops from the tissues of the thyroid gland. It is a disease in which... more...

Related Diseases for Thyroid Cancer

Diseases related to Thyroid Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 268)
# Related Disease Score Top Affiliating Genes
1 thyroid cancer, nonmedullary, 2 35.7 BRAF HRAS NRAS RET
2 thyroid carcinoma, familial medullary 34.2 KRAS MALAT1 RET
3 thyroid cancer, nonmedullary, 1 32.7 BRAF GAS5 H19 HOTAIR MALAT1 NEAT1
4 differentiated thyroid carcinoma 31.9 BRAF HRAS KRAS NRAS RET
5 malignant struma ovarii 31.7 HRAS NRAS RET
6 ovarian germ cell teratoma 31.5 NRAS RET
7 benign struma ovarii 31.4 HRAS NRAS RET
8 giant congenital nevus 31.3 HRAS NRAS
9 adrenocortical carcinoma, hereditary 31.1 BRAF H19 NRAS
10 sarcoma 30.9 BRAF HOTAIR HRAS KRAS
11 struma ovarii 30.9 BRAF RET
12 glioblastoma 29.7 BRAF GAS5 H19 HOTAIR HRAS MALAT1
13 melanoma 29.6 BRAF CDKN2B-AS1 GAS5 H19 HOTAIR MALAT1
14 kidney cancer 29.5 GAS5 H19 HOTAIR MALAT1 PVT1
15 squamous cell carcinoma 29.2 BRAF CDKN2B-AS1 H19 HOTAIR HRAS KRAS
16 leukemia 28.6 CDKN2B-AS1 GAS5 HOTAIR MLF1 NEAT1 NRAS
17 breast cancer 27.3 BRAF CASC2 CDKN2B-AS1 GAS5 H19 HOTAIR
18 lung cancer 25.2 AFAP1-AS1 BRAF CASC2 CDKN2B-AS1 GAS5 H19
19 anaplastic thyroid cancer 12.4
20 thyroid cancer, nonmedullary, 5 12.3
21 thyroid cancer, nonmedullary, 4 12.3
22 thyroid cancer, nonmedullary, 3 12.3
23 thyroid cancer, childhood 12.1
24 thyroid carcinoma, hurthle cell 11.7
25 schimmelpenning-feuerstein-mims syndrome 11.4 HRAS KRAS NRAS
26 nevus, epidermal 11.4 HRAS KRAS NRAS
27 acneiform dermatitis 11.4 HRAS KRAS NRAS
28 adenosquamous cell lung carcinoma 11.4 HRAS KRAS RET
29 core binding factor acute myeloid leukemia 11.4 HRAS KRAS NRAS
30 liver angiosarcoma 11.4 HRAS KRAS NRAS
31 sigmoid neoplasm 11.4 HRAS KRAS
32 pulmonic stenosis 11.3 BRAF HRAS KRAS
33 skin squamous cell carcinoma 11.3 BRAF HRAS KRAS
34 noonan syndrome 1 11.3 BRAF HRAS KRAS NRAS
35 ovarian serous cystadenocarcinoma 11.3 BRAF HRAS NRAS
36 cardiofaciocutaneous syndrome 1 11.3 BRAF HRAS KRAS
37 renal cell carcinoma, papillary, 1 11.3 BRAF HRAS NRAS
38 cell type benign neoplasm 11.3 HRAS KRAS RET
39 apocrine adenoma 11.3 HRAS KRAS
40 colorectal adenocarcinoma 11.3 BRAF HRAS KRAS
41 endocrine gland cancer 11.3 HRAS KRAS RET
42 cell type cancer 11.2 HRAS KRAS NRAS
43 periampullary adenoma 11.2 HRAS KRAS
44 paronychia 11.2 HRAS KRAS
45 hyperplastic polyposis syndrome 11.2 BRAF KRAS
46 ovarian melanoma 11.2 HRAS NRAS
47 hypothyroidism 11.2
48 pilocytic astrocytoma 11.2 BRAF HRAS KRAS
49 spitz nevus 11.2 BRAF HRAS
50 thyroiditis 11.2

Comorbidity relations with Thyroid Cancer via Phenotypic Disease Network (PDN):


Hypertension, Essential Hypothyroidism
Lymphomatous Thyroiditis Postsurgical Hypothyroidism

Graphical network of the top 20 diseases related to Thyroid Cancer:



Diseases related to Thyroid Cancer

Symptoms & Phenotypes for Thyroid Cancer

UMLS symptoms related to Thyroid Cancer:


coughing, snoring, tinnitus, sore throat, vertigo/dizziness, equilibration disorder

Drugs & Therapeutics for Thyroid Cancer

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Cometriq 18 49 CABOZANTINIB S-MALATE Exelixis November 2012
2
Lenvima 18 49 LENVATINIB MESYLATE Eisai February 2015
3
Nexavar 18 49 SORAFENIB TOSYLATE Bayer/Onyx December 2005
4
Vandetanib 18 49 vandetanib AstraZeneca April 2011

Drugs for Thyroid Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 381)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iodine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 7553-56-2 807
2
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
3
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 1 439-14-5 3016
4
Sevoflurane Approved, Vet_approved Phase 4,Not Applicable 28523-86-6 5206
5
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
6
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1 77-92-9 311
7 cadexomer iodine Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
8 Betamethasone Valerate Phase 4 2152-44-5
9 Analgesics Phase 4,Phase 2,Not Applicable
10 glucocorticoids Phase 4,Phase 1,Phase 2
11 Respiratory System Agents Phase 4,Phase 3
12 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Micronutrients Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
14 Anesthetics Phase 4,Phase 3,Phase 1,Not Applicable
15 Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
16 Trace Elements Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
17 Hormones Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
18 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
19 Anti-Asthmatic Agents Phase 4,Phase 3
20 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable
21 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
22 Anti-Infective Agents, Local Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
23 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 1,Not Applicable
24 Betamethasone acetate Phase 4
25 Betamethasone benzoate Phase 4
26 Betamethasone sodium phosphate Phase 4
27 Betamethasone-17,21-dipropionate Phase 4
28 Adjuvants, Anesthesia Phase 4,Phase 1
29 Narcotics Phase 4,Not Applicable
30 Analgesics, Opioid Phase 4,Not Applicable
31 Anesthetics, General Phase 4,Phase 1,Not Applicable
32 Anesthetics, Intravenous Phase 4,Phase 1,Not Applicable
33 tyrosine Nutraceutical Phase 4,Phase 2,Phase 1
34 Citrate Nutraceutical Phase 4,Phase 2,Phase 1
35
Sorafenib Approved, Investigational Phase 3,Phase 2 284461-73-0 216239 406563
36
Paclitaxel Approved, Vet_approved Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1 33069-62-4 36314
37
Salmon Calcitonin Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 47931-85-1 16129616
38
Lenvatinib Approved, Investigational Phase 3,Phase 2,Phase 1 417716-92-8
39
Zinc Approved, Investigational Phase 3,Not Applicable 7440-66-6 23994
40
Metformin Approved Phase 3,Phase 2,Not Applicable 657-24-9 14219 4091
41
Carboplatin Approved Phase 2, Phase 3,Phase 3,Phase 1 41575-94-4 10339178 498142 38904
42
Ropivacaine Approved Phase 3,Not Applicable 84057-95-4 71273 175805
43
Epinephrine Approved, Vet_approved Phase 3,Phase 2 51-43-4 5816
44
Insulin Glargine Approved Phase 3 160337-95-1
45 Dulaglutide Approved, Investigational Phase 3 923950-08-7
46
Racepinephrine Approved Phase 3,Phase 2 329-65-7 838
47
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
48
Nicotinamide Approved, Investigational, Nutraceutical Phase 3,Phase 2 98-92-0 936
49
Niacin Approved, Investigational, Nutraceutical Phase 3,Phase 2 59-67-6 938
50
Calcitonin gene-related peptide Investigational Phase 3,Phase 2,Phase 1,Not Applicable 83652-28-2

Interventional clinical trials:

(show top 50) (show all 607)
# Name Status NCT ID Phase Drugs
1 rAd-p53 Gene Therapy for Advanced Malignant Thyroid Tumors Unknown status NCT00902122 Phase 4 rAd-p53 gene;p53 gene therapy
2 Total Thyroidectomy With Harmonic Scalpel® Unknown status NCT00385983 Phase 4
3 Steroids in the Postoperative Transient Hypoparathyroidism Total Thyroidectomy Unknown status NCT02652884 Phase 4 phosphate and betamethasone acetate, 2 mL.;saline 0.9% NaCl
4 Quality of Life, Recombinant TSH (Thyrogen) and Thyroid Cancer Completed NCT00604318 Phase 4 rhTSH
5 Study of Radioiodine (131-I) Uptake Following Administration of Thyrogen and Hypothyroid States During Thyroid Hormone Withdrawal. Completed NCT00001730 Phase 4 Thyrogen
6 Dose-dependent Effect of Fentanyl on Cough Attenuation During Emergence From General Anaesthesia Completed NCT01308320 Phase 4 fentanyl citrate;saline
7 Is the Routine Pressure Dressing After Thyroidectomy Necessary? Completed NCT00400465 Phase 4
8 Percutaneous Laser Ablation in Benign Thyroid Nodules.Long Term Results Completed NCT00858104 Phase 4
9 A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer Recruiting NCT03573960 Phase 4 Lenvatinib
10 Radiolabeled Molecules for Medullary Thyroid Cancer Recruiting NCT01915485 Phase 4
11 A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer Recruiting NCT01896479 Phase 4 Cabozantinib (XL184) 140 mg;Cabozantinib (XL184) 60 mg;Placebo tablet;Placebo capsule
12 Levothyroxine Replacement With Liquid Gel Capsules vs Tablets Post-thyroidectomy Recruiting NCT02946918 Phase 4 Levothyroxine
13 Minimizing Narcotic Analgesics After Endocrine Surgery Recruiting NCT03469310 Phase 4 Acetaminophen 500Mg Cap;Tylenol #3 Oral Tablet;Tramadol
14 To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer Active, not recruiting NCT01496313 Phase 4 300mg vandetanib;150mg vandetanib
15 Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer Unknown status NCT00704730 Phase 3 XL184;Placebo
16 Medico-Economic Comparison of Four Strategies of Radioiodine Ablation in Thyroid Carcinoma Patients Unknown status NCT00435851 Phase 3 Thyrogen, thyroid hormone withdrawal, iode 131
17 Medico-economic Evaluation Comparing the Use of Ultrasonic Scissors to the Conventional Techniques of Haemostasis in Thyroid Surgery by Cervicotomy Unknown status NCT01551914 Phase 3
18 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors Unknown status NCT01373736 Phase 3 123I-meta-iodobenzylguanidine
19 Laser Therapy of Benign Thyroid Nodules Unknown status NCT00150150 Phase 3
20 Decision Making on Radioactive Iodine Treatment for Papillary Thyroid Cancer Completed NCT01083550 Phase 2, Phase 3
21 A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen. Completed NCT00295763 Phase 3 Thyrogen (thyrotropin alfa for injection)
22 The Usefulness of Staining Lymph Nodes During Operations for Cancer Thyroid in Detecting the Nodes That Have Cancer Completed NCT00794053 Phase 3
23 Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer Completed NCT00984282 Phase 3 Sorafenib (Nexavar, BAY43-9006);Placebo
24 Multicenter Study Differentiated Thyroid Carcinoma Completed NCT00144079 Phase 3
25 Lateral Neck Sentinel Lymph Node Biopsy(LSLNB)in PTC Completed NCT01137097 Phase 2, Phase 3
26 Efficacy of Subfascial Approach in Thyroidectomy to Quality of Life in Thyroid Disease Patients Completed NCT01616316 Phase 2, Phase 3
27 Prophylactic Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma Completed NCT00795782 Phase 3
28 Comparison of the Safety and Successful Ablation of Thyroid Remnant in Post-thyroidectomized Euthyroid Patients (i.e. Patients Administered Thyrogen) Versus Hypothyroid Patients (no Thyrogen) Following 131I Administration Completed NCT00196729 Phase 3 Thyrogen + Radioiodine (131I)
29 Efficacy of Ropivacaine (With Epinephrine) in BABA Endoscopic and Robotic Thyroidectomy Completed NCT02112370 Phase 3 Ropivacaine with epinephrine injection
30 Efficacy of Fibrin Sealant to Reduce the Amount of Post-thyroidectomy Drain Completed NCT01126060 Phase 3 Usage of Fibrin sealant
31 Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Cancer or Suspected Cancer Completed NCT00123760 Phase 2, Phase 3
32 Cinacalcet to Treat Familial Primary Hyperparathyroidism Completed NCT00325104 Phase 3
33 A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes Completed NCT02152371 Phase 3 Dulaglutide;Placebo;Insulin Glargine;Metformin
34 Percutaneous Radiofrequency Thermal Ablation in Compressive Thyroid Nodules Completed NCT01649206 Phase 3
35 Elastography Interest in the Management of Thyroid Nodules Completed NCT01335828 Phase 2, Phase 3
36 Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032) Recruiting NCT02586337 Phase 2, Phase 3 Anlotinib;Placebo
37 Efficacy of Apatinib in Radioactive Iodine-refractory Differentiated Thyroid Cancer Recruiting NCT03048877 Phase 3 Apatinib Oral Tablet;Placebo Oral Tablet
38 IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients Recruiting NCT01398085 Phase 2, Phase 3
39 A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in China Recruiting NCT02966093 Phase 3 Lenvatinib;Placebo
40 Differentiated Thyroid Cancer: is There a Need for Radioiodine Ablation in Low Risk Patients? Recruiting NCT01837745 Phase 3 rhTSH stimulation;I131
41 Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031) Recruiting NCT02586350 Phase 2, Phase 3 Anlotinib;Placebo
42 Extent of Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma Recruiting NCT01149161 Phase 2, Phase 3
43 Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer Active, not recruiting NCT01843062 Phase 3 Selumetinib;Placebo;Radioactive Iodine Therapy
44 Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer Active, not recruiting NCT01876784 Phase 3 Vandetanib (SAR390530);Placebo
45 Minimize Radioactive Iodine Ablation Of Remnant Thyroid in Differentiated Thyroid Cancer Active, not recruiting NCT02418247 Phase 2, Phase 3 I131;I123
46 An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer Active, not recruiting NCT00410761 Phase 3 ZD6474 (Vandetanib)
47 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC) Active, not recruiting NCT01321554 Phase 3 Lenvatinib;Placebo;Lenvatinib
48 Iodine I 131 With or Without Thyroid-Stimulating Hormone in Treating Patients Who Have Undergone Surgery for Thyroid Cancer Active, not recruiting NCT00415233 Phase 3
49 The Dose of Radioactive Iodine Needed to Ablate the Thyroid Remnant Left Behind After Thyroidectomy Active, not recruiting NCT00115895 Phase 3 Radioactive iodine
50 Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment Active, not recruiting NCT01298323 Phase 3 Vandetanib

Search NIH Clinical Center for Thyroid Cancer

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: thyroid neoplasms

Genetic Tests for Thyroid Cancer

Genetic tests related to Thyroid Cancer:

# Genetic test Affiliating Genes
1 Thyroid Carcinoma 29
2 Neoplasm of the Thyroid Gland 29
3 Thyroid Cancer 29

Anatomical Context for Thyroid Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Thyroid Cancer:

19
The Thryoid Gl

MalaCards organs/tissues related to Thyroid Cancer:

41
Thyroid, Lymph Node, Testes, Endothelial, Lung, Bone, Liver

Publications for Thyroid Cancer

Articles related to Thyroid Cancer:

(show top 50) (show all 2334)
# Title Authors Year
1
Teriparatide Replacement Therapy for Hypoparathyroidism During Treatment With Lenvatinib for Advanced Thyroid Cancer: A Case Report. ( 29867775 )
2018
2
Posterior reversible encephalopathy syndrome and takotsubo cardiomyopathy associated with lenvatinib therapy for thyroid cancer: a case report and review. ( 29963277 )
2018
3
Sphingosine 1-phosphate attenuates MMP2 and MMP9 in human anaplastic thyroid cancer C643 cells: Importance of S1P2. ( 29734379 )
2018
4
How deep is our anxiety during treatment of thyroid cancer? ( 29972434 )
2018
5
CRISPR/Cas9 Genome Editing of Epidermal Growth Factor Receptor Sufficiently Abolished Oncogenicity in Anaplastic Thyroid Cancer. ( 29849821 )
2018
6
mRNA Expression of SLC5A5 and SLC2A Family Genes in Papillary Thyroid Cancer: An Analysis of The Cancer Genome Atlas. ( 29978611 )
2018
7
Combined Effects of Baicalein and Docetaxel on Apoptosis in 8505c Anaplastic Thyroid Cancer Cells via Downregulation of the ERK and Akt/mTOR Pathways. ( 29589394 )
2018
8
Ultrasound features of extranodal extension in the metastatic cervical lymph nodes of papillary thyroid cancer: a case-control study. ( 29951341 )
2018
9
Thyroid cancer stem-like cell exosomes: regulation of EMT via transfer of lncRNAs. ( 29967342 )
2018
10
Cost Effectiveness of Routine Laryngoscopy in the Surgical Treatment of Differentiated Thyroid Cancer. ( 29417402 )
2018
11
Inhibiting 6-phosphogluconate dehydrogenase reverses doxorubicin resistance in anaplastic thyroid cancer via inhibiting NADPH-dependent metabolic reprogramming. ( 29534964 )
2018
12
The Outcome of Papillary Thyroid Cancer Associated with Graves' Disease: A Case Control Study. ( 29854383 )
2018
13
Neurotrophin Receptors TrkA, p75<sup>NTR</sup>, and Sortilin Are Increased and Targetable in Thyroid Cancer. ( 29037860 )
2018
14
Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo. ( 29517106 )
2018
15
Prostate-specific Membrane Antigen Imaging in Recurrent Medullary Thyroid Cancer: A New Theranostic Tracer in the Offing? ( 29962733 )
2018
16
Evolution in the management of thyroid cancer: an observational study in two referral centres in Belgium. ( 29431057 )
2018
17
Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo. ( 29517103 )
2018
18
miR-27b-3p is Involved in Doxorubicin resistance of Human Anaplastic Thyroid Cancer Cells via Targeting PPARI^. ( 29924913 )
2018
19
The Role of Different Molecular Markers in Papillary Thyroid Cancer Patients with Acromegaly. ( 29890543 )
2018
20
MiR-524 inhibits cell proliferation and induces cell apoptosis in thyroid cancer via targeting SPAG9. ( 29949157 )
2018
21
LAMB3 mediates metastatic tumor behavior in papillary thyroid cancer by regulating c-MET/Akt signals. ( 29426928 )
2018
22
A Case of Pneumothorax after Treatment with Lenvatinib for Anaplastic Thyroid Cancer with Lung Metastasis. ( 29796324 )
2018
23
Bromodomaina89containing proteinA 4 is critical for the antiproliferative and proa89apoptotic effects of gambogic acid in anaplastic thyroid cancer. ( 29717765 )
2018
24
A Synergistic Anti-Cancer Effect of Troglitazone and Lovastatin in a Human Anaplastic Thyroid Cancer Cell Line and in a Mouse Xenograft Model. ( 29932104 )
2018
25
Resveratrol Suppresses the Growth and Enhances Retinoic Acid Sensitivity of Anaplastic Thyroid Cancer Cells. ( 29596381 )
2018
26
Treatment and survival vary by race/ethnicity in patients with anaplastic thyroid cancer. ( 29409119 )
2018
27
Identification of BAG3 target proteins in anaplastic thyroid cancer cells by proteomic analysis. ( 29487711 )
2018
28
Synchronous papillary thyroid cancer and non-Hodgkin lymphoma: Case report. ( 29419687 )
2018
29
Anti-<i>hTERT</i> siRNA-Loaded Nanoparticles Block the Growth of Anaplastic Thyroid Cancer Xenograft. ( 29563163 )
2018
30
The role of EIF1AX in thyroid cancer tumourigenesis and progression. ( 29968046 )
2018
31
Effects of different extracts of curcumin on TPC1 papillary thyroid cancer cell line. ( 29448931 )
2018
32
TERT promoter mutations and their correlation with BRAF and RAS mutations in a consecutive cohort of 145 thyroid cancer cases. ( 29435002 )
2018
33
Hypofractionated Radiotherapy Is Superior to Conventional Fractionation in an Orthotopic Model of Anaplastic Thyroid Cancer. ( 29774792 )
2018
34
Thyroid cancer risk in the Swedish AMORIS study: the role of inflammatory biomarkers in serum. ( 29416653 )
2018
35
Role of thyroid ultrasound combined with thyroglobulin in the diagnosis of postoperative recurrence of thyroid cancer. ( 29442477 )
2018
36
Successful treatment of a diffuse type tenosynovial giant cell tumor in the thoracic spine mimicking spinal metastasis by frozen recapping laminoplasty in a patient with thyroid cancer. ( 29663145 )
2018
37
The Effect of Lithium on the Progression Free and Overall Survival in Patients with Metastatic Differentiated Thyroid Cancer Undergoing Radioactive Iodine Therapy. ( 29972703 )
2018
38
J-shaped Association between Post-operative Levothyroxine Dosage and Fracture Risk in Thyroid Cancer Patients: a Retrospective Cohort Study. ( 29447437 )
2018
39
The role of radioactive iodine therapy in papillary thyroid cancer: an observational study based on SEER. ( 29950860 )
2018
40
Long noncoding RNA CNALPTC1 promotes cell proliferation and migration of papillary thyroid cancer via sponging miR-30 family. ( 29416932 )
2018
41
Predictive relevance of programmed cell death protein 1 and tumor-infiltrating lymphocyte expression in papillary thyroid cancer. ( 29128181 )
2018
42
Cutaneous squamous cell carcinoma, thyroid cancer and Langerhans cell histiocytosis in a patient with X-linked recessive Mendelian susceptibility to mycobacterial diseases with a nuclear factor-I_B essential modifier mutation. ( 29797522 )
2018
43
Long Noncoding RNA LINC003121 Inhibits Proliferation and Invasion of Thyroid Cancer Cells by Suppression of the Phosphatidylinositol-3-Kinase (PI3K)/Akt Signaling Pathway. ( 29969438 )
2018
44
Up-regulation of miR-340-5p promotes progression of thyroid cancer by inhibiting BMP4. ( 29441462 )
2018
45
LncRNA PTCSC3 affects drug resistance of anaplastic thyroid cancer through STAT3/INO80 pathway. ( 29561707 )
2018
46
Suppressed thyroglobulin performs better than stimulated thyroglobulin in defining an excellent response in patients with differentiated thyroid cancer. ( 29438217 )
2018
47
<i>ETV6-NTRK3</i> and <i>STRN-ALK</i> kinase fusions are recurrent events in papillary thyroid cancer of adult population. ( 29046324 )
2018
48
Role of Chemokines in Thyroid Cancer Microenvironment: Is CXCL8 the Main Player? ( 29977225 )
2018
49
Unusual Uptake of 131I in a Cutaneous Benign Fibrous Histiocytoma in a Patient With Thyroid Cancer. ( 29076899 )
2018
50
LRIG1 negatively regulates RET mutants and is downregulated in thyroid cancer. ( 29436694 )
2018

Variations for Thyroid Cancer

ClinVar genetic disease variations for Thyroid Cancer:

6
(show top 50) (show all 82)
# Gene Variation Type Significance SNP ID Assembly Location
1 KRAS NM_033360.3(KRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913530 GRCh37 Chromosome 12, 25398285: 25398285
2 KRAS NM_033360.3(KRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913530 GRCh38 Chromosome 12, 25245351: 25245351
3 KRAS NM_033360.3(KRAS): c.34G> C (p.Gly12Arg) single nucleotide variant Pathogenic rs121913530 GRCh37 Chromosome 12, 25398285: 25398285
4 KRAS NM_033360.3(KRAS): c.34G> C (p.Gly12Arg) single nucleotide variant Pathogenic rs121913530 GRCh38 Chromosome 12, 25245351: 25245351
5 KRAS NM_033360.3(KRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic rs112445441 GRCh37 Chromosome 12, 25398281: 25398281
6 KRAS NM_033360.3(KRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic rs112445441 GRCh38 Chromosome 12, 25245347: 25245347
7 KRAS NM_004985.4(KRAS): c.35G> A (p.Gly12Asp) single nucleotide variant Pathogenic rs121913529 GRCh37 Chromosome 12, 25398284: 25398284
8 KRAS NM_004985.4(KRAS): c.35G> A (p.Gly12Asp) single nucleotide variant Pathogenic rs121913529 GRCh38 Chromosome 12, 25245350: 25245350
9 KRAS NM_004985.4(KRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic rs121913529 GRCh37 Chromosome 12, 25398284: 25398284
10 KRAS NM_004985.4(KRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic rs121913529 GRCh38 Chromosome 12, 25245350: 25245350
11 KRAS NM_033360.3(KRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs121913530 GRCh37 Chromosome 12, 25398285: 25398285
12 KRAS NM_033360.3(KRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs121913530 GRCh38 Chromosome 12, 25245351: 25245351
13 KRAS NM_033360.3(KRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic rs121913535 GRCh37 Chromosome 12, 25398282: 25398282
14 KRAS NM_033360.3(KRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic rs121913535 GRCh38 Chromosome 12, 25245348: 25245348
15 HRAS NM_005343.3(HRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
16 HRAS NM_005343.3(HRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic rs104894230 GRCh38 Chromosome 11, 534288: 534288
17 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
18 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
19 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
20 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh38 Chromosome 11, 534288: 534288
21 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
22 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh38 Chromosome 11, 534286: 534286
23 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
24 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
25 RET NM_020630.4(RET): c.1902C> G (p.Cys634Trp) single nucleotide variant Pathogenic rs77709286 GRCh37 Chromosome 10, 43609950: 43609950
26 RET NM_020630.4(RET): c.1902C> G (p.Cys634Trp) single nucleotide variant Pathogenic rs77709286 GRCh38 Chromosome 10, 43114502: 43114502
27 RET NM_020975.4(RET): c.2753T> C (p.Met918Thr) single nucleotide variant Pathogenic rs74799832 GRCh37 Chromosome 10, 43617416: 43617416
28 RET NM_020975.4(RET): c.2753T> C (p.Met918Thr) single nucleotide variant Pathogenic rs74799832 GRCh38 Chromosome 10, 43121968: 43121968
29 BRAF NM_004333.4(BRAF): c.1801A> G (p.Lys601Glu) single nucleotide variant Pathogenic rs121913364 GRCh37 Chromosome 7, 140453134: 140453134
30 BRAF NM_004333.4(BRAF): c.1801A> G (p.Lys601Glu) single nucleotide variant Pathogenic rs121913364 GRCh38 Chromosome 7, 140753334: 140753334
31 AKT1 NM_005163.2(AKT1): c.49G> A (p.Glu17Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121434592 GRCh37 Chromosome 14, 105246551: 105246551
32 AKT1 NM_005163.2(AKT1): c.49G> A (p.Glu17Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121434592 GRCh38 Chromosome 14, 104780214: 104780214
33 HRAS NM_005343.3(HRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
34 HRAS NM_005343.3(HRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs104894228 GRCh38 Chromosome 11, 534286: 534286
35 BRAF NM_004333.4(BRAF): c.1802A> C (p.Lys601Thr) single nucleotide variant Pathogenic/Likely pathogenic rs397507484 GRCh37 Chromosome 7, 140453133: 140453133
36 BRAF NM_004333.4(BRAF): c.1802A> C (p.Lys601Thr) single nucleotide variant Pathogenic/Likely pathogenic rs397507484 GRCh38 Chromosome 7, 140753333: 140753333
37 KRAS NM_033360.3(KRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic rs121913240 GRCh37 Chromosome 12, 25380276: 25380276
38 KRAS NM_033360.3(KRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic rs121913240 GRCh38 Chromosome 12, 25227342: 25227342
39 KRAS NM_033360.3(KRAS): c.182A> T (p.Gln61Leu) single nucleotide variant Pathogenic rs121913240 GRCh37 Chromosome 12, 25380276: 25380276
40 KRAS NM_033360.3(KRAS): c.182A> T (p.Gln61Leu) single nucleotide variant Pathogenic rs121913240 GRCh38 Chromosome 12, 25227342: 25227342
41 KRAS NM_033360.3(KRAS): c.183A> T (p.Gln61His) single nucleotide variant Pathogenic/Likely pathogenic rs17851045 GRCh37 Chromosome 12, 25380275: 25380275
42 KRAS NM_033360.3(KRAS): c.183A> T (p.Gln61His) single nucleotide variant Pathogenic/Likely pathogenic rs17851045 GRCh38 Chromosome 12, 25227341: 25227341
43 KRAS NM_033360.3(KRAS): c.38G> T (p.Gly13Val) single nucleotide variant drug response rs112445441 GRCh37 Chromosome 12, 25398281: 25398281
44 KRAS NM_033360.3(KRAS): c.38G> T (p.Gly13Val) single nucleotide variant drug response rs112445441 GRCh38 Chromosome 12, 25245347: 25245347
45 PIK3CA NM_006218.3(PIK3CA): c.353G> A (p.Gly118Asp) single nucleotide variant Pathogenic/Likely pathogenic rs587777790 GRCh38 Chromosome 3, 179199690: 179199690
46 PIK3CA NM_006218.3(PIK3CA): c.353G> A (p.Gly118Asp) single nucleotide variant Pathogenic/Likely pathogenic rs587777790 GRCh37 Chromosome 3, 178917478: 178917478
47 HRAS NM_005343.3(HRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Likely pathogenic rs121913233 GRCh38 Chromosome 11, 533874: 533874
48 HRAS NM_005343.3(HRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Likely pathogenic rs121913233 GRCh37 Chromosome 11, 533874: 533874
49 PIK3CA NM_006218.3(PIK3CA): c.3129G> A (p.Met1043Ile) single nucleotide variant Likely pathogenic rs121913283 GRCh37 Chromosome 3, 178952074: 178952074
50 PIK3CA NM_006218.3(PIK3CA): c.3129G> A (p.Met1043Ile) single nucleotide variant Likely pathogenic rs121913283 GRCh38 Chromosome 3, 179234286: 179234286

Copy number variations for Thyroid Cancer from CNVD:

7 (show all 22)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 48476 11 1 43400000 Gain Thyroid cancer
2 75266 13 18400000 72100000 Loss Thyroid cancer
3 80538 13 93800000 114142980 Loss Thyroid cancer
4 85051 14 37800000 43500000 Copy number FOXA1 Thyroid cancer
5 96631 15 90931472 91045475 Amplificationlicatio n IQGAP1 Thyroid cancer
6 111285 17 35400000 68400000 Gain Thyroid cancer
7 120295 18 23300000 71300000 Loss Thyroid cancer
8 150420 20 1 27100000 Amplification Thyroid cancer
9 151957 20 27100000 62435964 Amplification Thyroid cancer
10 153452 20 37100000 62435964 Gain Thyroid cancer
11 171643 3 170900000 182700000 Gain PIK3CA Thyroid cancer
12 171644 3 170900000 182700000 Gain PIK3CA Thyroid cancer
13 191662 5 1 45800000 Amplification Thyroid cancer
14 191664 5 1 45800000 Gain Thyroid cancer
15 200481 5 55800000 180857866 Gain Thyroid cancer
16 201091 5 65300000 159900000 Amplification Thyroid cancer
17 217036 7 1 158821424 Amplification Thyroid cancer
18 230743 8 1 19100000 Loss Thyroid cancer
19 236403 8 16100000 117700000 Amplification Thyroid cancer
20 236404 8 16100000 146274826 Gain Thyroid cancer
21 261707 X 24900000 59500000 Loss Thyroid cancer
22 303365 21 26028751 26066642 Deletion NRF2 Thyroid cancer

Expression for Thyroid Cancer

Search GEO for disease gene expression data for Thyroid Cancer.

Pathways for Thyroid Cancer

Pathways related to Thyroid Cancer according to KEGG:

37
# Name Kegg Source Accession
1 Thyroid cancer hsa05216
2 Transcriptional misregulation in cancer hsa05202

Pathways related to Thyroid Cancer according to GeneCards Suite gene sharing:

(show all 50)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.83 BRAF HRAS KRAS NRAS RET
2 12.79 BRAF HRAS KRAS NRAS RET
3
Show member pathways
12.48 BRAF HRAS KRAS NRAS
4
Show member pathways
12.47 BRAF HRAS KRAS NRAS SDC4
5
Show member pathways
12.44 BRAF HRAS KRAS NRAS
6
Show member pathways
12.41 HRAS KRAS NRAS SDC4
7
Show member pathways
12.4 BRAF HRAS KRAS NRAS
8
Show member pathways
12.39 BRAF HRAS KRAS NRAS
9
Show member pathways
12.36 BRAF HRAS KRAS SDC4
10
Show member pathways
12.34 BRAF HRAS KRAS NRAS
11
Show member pathways
12.26 BRAF HRAS KRAS NRAS
12
Show member pathways
12.24 BRAF HRAS KRAS NRAS
13
Show member pathways
12.2 HRAS KRAS NRAS SDC4
14
Show member pathways
12.18 BRAF HRAS KRAS NRAS
15 12.18 BRAF HRAS KRAS NRAS SDC4
16
Show member pathways
12.16 BRAF HRAS KRAS NRAS
17
Show member pathways
12.15 BRAF HRAS KRAS NRAS
18
Show member pathways
12.12 BRAF HRAS KRAS NRAS
19
Show member pathways
12.06 BRAF HRAS KRAS NRAS
20
Show member pathways
12.05 BRAF HRAS KRAS NRAS
21 12.03 BRAF HRAS KRAS NRAS
22
Show member pathways
11.98 HRAS KRAS NRAS RET
23 11.94 HRAS KRAS NRAS
24 11.93 BRAF HRAS KRAS NRAS
25 11.92 BRAF HRAS KRAS NRAS
26
Show member pathways
11.91 HRAS KRAS NRAS
27 11.9 BRAF HRAS KRAS NRAS
28 11.87 HRAS KRAS NRAS
29
Show member pathways
11.82 HRAS KRAS NRAS
30
Show member pathways
11.81 HRAS KRAS NRAS
31 11.79 HRAS KRAS NRAS
32 11.65 HRAS KRAS NRAS
33 11.62 BRAF HRAS KRAS NRAS
34 11.57 HRAS KRAS NRAS
35 11.55 HRAS KRAS NRAS RET
36
Show member pathways
11.52 BRAF HRAS KRAS NRAS
37 11.4 BRAF HRAS KRAS NRAS
38 11.28 HRAS KRAS NRAS
39 11.24 HRAS KRAS NRAS
40 11.24 HRAS KRAS NRAS
41 11.24 HRAS KRAS NRAS RET
42
Show member pathways
11.19 HRAS KRAS NRAS
43
Show member pathways
11.13 HRAS KRAS NRAS
44 11.08 BRAF HRAS KRAS NRAS
45 11.06 HRAS KRAS NRAS
46 11.03 HRAS KRAS NRAS
47 10.97 HRAS KRAS NRAS
48
Show member pathways
10.94 BRAF HRAS KRAS NRAS RET
49 10.79 BRAF HRAS KRAS NRAS
50 10.66 HRAS KRAS NRAS

GO Terms for Thyroid Cancer

Biological processes related to Thyroid Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 leukocyte migration GO:0050900 9.71 HRAS KRAS NRAS SDC4
2 axon guidance GO:0007411 9.67 HRAS KRAS NRAS RET
3 Ras protein signal transduction GO:0007265 9.61 HRAS KRAS NRAS
4 epidermal growth factor receptor signaling pathway GO:0007173 9.5 HRAS KRAS NRAS
5 response to isolation stress GO:0035900 9.26 HRAS KRAS
6 myeloid progenitor cell differentiation GO:0002318 9.16 BRAF MLF1
7 ERBB2 signaling pathway GO:0038128 9.13 HRAS KRAS NRAS
8 MAPK cascade GO:0000165 9.02 BRAF HRAS KRAS NRAS RET

Molecular functions related to Thyroid Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleotide binding GO:0000166 9.02 BRAF HRAS KRAS NRAS RET

Sources for Thyroid Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....